LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Lixte Biotechnology Holdings is a clinical-stage biopharmaceutical company developing cancer therapeutics. The company's primary focus is identifying molecular targets for oncology drug development and advancing drug candidates through clinical testing. Its lead asset, LB-100, is currently in Phase 1b clinical trials across multiple indications, including microsatellite stable metastatic colorectal cancer combined with Atezolizumab, advanced soft tissue sarcoma in combination with doxorubicin, and ovarian clear cell carcinoma paired with dostarlimab.

The company operates through clinical collaboration agreements with research institutions, including the Netherlands Cancer Institute and the Spanish Sarcoma Group. These partnerships provide infrastructure for investigator-initiated and company-sponsored trials. Lixte has not yet generated commercial revenues as its portfolio remains in early-stage development.

The company is headquartered in Pasadena, California, and operates with a minimal employee base of two full-time staff members, consistent with a clinical-stage organization dependent on external research partnerships and contract research organizations for trial execution. Founded in 2005 and incorporated in Delaware, Lixte is listed on the Nasdaq exchange.